Gefitinib Intermedia CAS 199327-61-2 Puritas >99.0% (HPLC)
Shanghai Ruifu Chemical Co., Ltd. est primarius fabrica 7-Methoxy-6-(3-Morpholin-4-ylpropoxy)quinazolin-4(3H)-Unus (CAS: 199327-61-2) cum qualitate, media de Gefitinib (CAS: 184475-35-2).Ruifu Chemical traditio totius terrarum, quantitatis competitive pretium, optimum servitium, parvas et moles in promptu habere potest.Purchase Gefitinib Mediis,Please contact: alvin@ruifuchem.com
| Nomen chemicum | 7-Methoxy-6-(3-Morpholin-4-ylpropoxy)quinazolin-4(3H)unum |
| Synonyma | 7-Methoxy-6-(3-Morpholinopropoxy)quinazolin-4(3H)-One;7-Methoxy-6-[3-(4-Morpholinyl)propoxy]-4(3H)-Quinazolinone;7-Methoxy-6-(3-Morpholinopropoxy)quinazolin-4-One |
| immunditia | impudicitia 5 gefitinib;Gefitinib EP Impuritas A |
| Stock Status | In Stock, Commercial Productio |
| CAS Number | 199327-61-2 |
| Formulae hypotheticae | C16H21N3O4 |
| M. Pondus | 319.36 g/mol |
| Liquescens punctum | 242.0~247.0℃ |
| Density | 1.32±0.10 g/cm3 |
| COA & MSDS | Praesto |
| Origin | Shanghai, China |
| Brand | Ruifu Chemical |
| Items | Signa inspectionis | Proventus |
| Aspectus | Alba ad Off-White pulveris | Obsequitur |
| Liquescens punctum | 242.0~247.0℃ | 243.6~244.5℃ |
| Damnum in Siccatio | <0.50% | 0.15% |
| Residere in Ignition | <0.20% | 0.11% |
| una immunditia | <0.50% | <0.30% |
| Totalis immunditias | <1.00% | 0.30% |
| Puritas / Analysis Methodus | >99.0% (HPLC) | 99.7% |
| 1H NMR Imaginum | Congruunt Structure | Obsequitur |
| conclusio | Productum probatum est et cum datis specificationibus obsequitur | |
| Applicationem | Medium Gefitinib (CAS: 184475-35-2) | |
Sarcina:Fluorinated Utrem, aluminium ffoyle, 25kg/cardboard Drum, vel secundum exigentiam emptoris.
Repono Condition:Continentem arcte clausam et in loco frigido, sicco (2~8℃) reponunt et a cellis bene ventilatis ab substantiis incompossibilibus.A luce et humore protege.
Naviportans:Libera ad mundum ab aere, per FedEx / DHL Express.Ieiunium et certas traditiones provide.
Quam mercari?Quaeso contactumDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience?Plus quam XV annos experientiae habemus in fabricando et exportando amplis intermediis pharmaceuticis vel alchimicis pharmaceuticis amplis.
Mercatus principalis?Vendere mercatum domesticum, Americam septentrionalem, Europam, Indiam, Coream, Iaponicam, Australiam etc.
Commodi?Superior qualitas, parabilis pretium, officia professionalia et subsidia technica, ieiunium partus.
Qualitasfides?Qualitas strictioris temperantiae ratio.Pro instrumento analysi professionali includuntur NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Claritas, Solubilitas, Microbialis limes test, etc.
Exempla?Pleraque producta praebent exempla gratuita pro qualitate aestimationis, sumptus naviculas a clientibus solvendos.
Factory Audit?Factory audit gratissimum.Quaeso ante constitutum.
MOQ?Nec MOQ.Parvus ordo placet.
Tempus adferendi? Si intus prosapia, tres dies partus praestatur.
Transportatio?Per Express (FedEx, DHL), ab Air, per Mare.
Documenta?Post servitium venditionis: COA, MOA, ROS, MSDS, etc. praeberi possunt.
Consuetudo Synthesis?Consuetudo synthesis officia praebere potest ad optimas investigationes tuas necessitates aptandas.
Pensio conditio?Proforma cautionis primum post confirmationem ordinis mittetur, informationes nostrae ripae inclusas.Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
7-Methoxy-6-(3-Morpholin-4-ylpropoxy)quinazolin-4(3H)-Onum (CAS: 199327-61-2) medium / immundum Gefitinib (CAS: 184475-35-2).Gefitinib pharmacum pharmacum therapeuticum anti-tumorem valde specificum ab AstraZeneca, UK evolvit.Gefitinib est primum medicamento iaculis hypotheticis pro curatione cancer pulmonis cellae non parvae.Operatur per selective inhibuit signum translationis per viam incrementi epidermalis factoris tyrosini kinasi receptoris (EGFR-TK).Mense Augusto 2002, Gefitinib primus in Iaponia venatus est ut curatio prima lineae cancri cellae pulmonis non parvae sub commercio nomine Iressa.Mense Maio MMIII, US Cibus et medicamentum Administrationis Gefitinib probavit sicut monotherapia tertia-linea aegris cum cancro cellulae pulmonali non-parvo provectae, qui inefficaces erant cum medicamentis platini-substructis anticancer et chemotherapy docetaxel.Nunc Gefitinib ab Australia, Iaponia, Argentina, Singapore et Corea Meridiana probata est ad tractationem cancri pulmonis non parvae cellae provectae.Die XXVIII mensis Februarii, MMV, Sinarum Food et Drug Administration Gefitinib probaverunt ad tractationem cancri localis progressi vel metastatici non-miniculi cancri pulmonis (NSCLC) qui chemotherapyam antea acceperat.Lorem usui primae lineae pro NSCLC provectae non est probatum.Die I mensis Iulii anno MMIX, Medicinae Europaeae Procuratio Gefitinib publice probata est pro linea, secunda-linea et tertia curatione locali provectae vel metastaticae cellae pulmonis non parvae cum EGFR mutationum generum in adultis.
